JSPR — Jasper Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1788028 ·
Last close
$0.56
Market Cap
$18.63M
52W High
$2.69
52W Low
$0.31
ADV30
364,655
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -9,207,000 | -2,760,000 | 11,802,000 | 7,314,000 | 10,389,000 |
| Mar 2026 | 0 | — | -10,952,000 | -1,174,000 | 21,184,000 | 14,144,000 | 17,784,000 |
| Dec 2025 | 0 | — | -15,839,000 | -9,101,000 | 35,779,000 | 28,692,000 | 31,628,000 |
| Sep 2025 | 0 | — | -19,166,000 | -18,736,000 | 57,469,000 | 50,899,000 | 45,898,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-68,867,000
Investing CF
$1,000
Financing CF
$34,211,000
CapEx
$-96,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.23
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-317,844,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-73,033,000
Pretax Income TTM
$-55,734,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -83,883,000 | -75,801,000 | 35,779,000 | 31,628,000 | 4,151,000 | -77,161,000 |
| Dec 2024 | 0 | -76,239,000 | -71,269,000 | 79,899,000 | 18,225,000 | 61,674,000 | -62,602,000 |
| Dec 2023 | 0 | -68,861,000 | -64,465,000 | 94,892,000 | 16,452,000 | 78,440,000 | -52,067,000 |
| Dec 2022 | 0 | -51,196,000 | -37,685,000 | 48,361,000 | 12,372,000 | 35,989,000 | -45,858,000 |
TTM Snapshot
Revenues TTM
$1,281,000
NetIncome TTM
$-55,734,000
OpCashFlow TTM
—
Assets (Latest)
$21,184,000
Forward EPS
$-2.56
Max Pain — expiry 2027-04-16
max pain strike: $0.50 · spot: $0.57 · call oi: 1,509 · put oi: 855
Expected Move to 2027-04-16:
±$0.43
(74.54%) —
implied range
$0.15 –
$1.00
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRML | Greenland Mines Ltd | $18.68M | $5.88 | — |
| ESLA | Estrella Immunopharma, Inc. | $18.16M | $0.42 | — |
| DYAI | DYADIC INTERNATIONAL INC | $17.80M | $0.44 | — |
| SCLX | Scilex Holding Co | $20.82M | $2.96 | — |
| BCDA | BioCardia, Inc. | $16.05M | $1.06 | — |
News headlines (Yahoo Finance, 1h cache)
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
2026-10-07 12:00 · Yahoo
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
2026-09-15 20:05 · Yahoo
Jasper Therapeutics beats Q2 expectations but shares fall after results
2026-08-17 12:30 · Yahoo
Jasper gets a lifeline in merger with immune drugmaker Kira
2026-07-17 11:54 · Yahoo
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 20:05 · Yahoo
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
2026-03-30 20:30 · Yahoo
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
2026-04-07 14:29 · Yahoo
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
2026-06-24 14:31 · Yahoo
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 12:00 · Yahoo
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-14 15:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.